FDA issues emergency authorization to use remdesivir as COVID-19 treatment

The drug will be given to coronavirus patients who are "hospitalized with severe disease."

Corinne Reichert Senior Writer
Corinne Reichert (she/her) grew up in Sydney, Australia and moved to California in 2019. She holds degrees in law and communications, and currently writes news, analysis and features for CNET across the topics of electric vehicles, broadband networks, mobile devices, big tech, artificial intelligence, home technology and entertainment. In her spare time, she watches soccer games and F1 races, and goes to Disneyland as often as possible.
Expertise News, mobile, broadband, 5G, home tech, streaming services, entertainment, AI, policy, business, politics Credentials
  • I've been covering technology and mobile for 12 years, first as a telecommunications reporter and assistant editor at ZDNet in Australia, then as CNET's West Coast head of breaking news, and now in the Thought Leadership team.
Corinne Reichert
2 min read

Remdesivir will be given to coronavirus patients who are "hospitalized with severe disease."

Ulrich Perrey / POOL / AFP

The US Food and Drug Administration has issued an emergency authorization for the drug remdesivir to be used in cases of COVID-19 where patients are "hospitalized with severe disease." The FDA made the announcement Friday afternoon, saying that while there's still limited information about the safety or effectiveness of the experimental drug, a clinical trial earlier this week showed a faster recovery time in some patients.

Remdesivir, an experimental antiviral drug produced by biotech firm Gilead Sciences, will be injected into suspected or confirmed coronavirus patients by health care providers where the patient has low blood oxygen levels, needs oxygen therapy or needs breathing support like a ventilator.

Health and Human Services Secretary Alex Azar called it "a significant step forward in battling COVID-19."

The approval comes just two days after the drug showed "clear-cut positive effect" in a US trial. The US National Institute of Allergy and Infectious Diseases said Wednesday that preliminary data from a US-based clinical trial showed it can help patients recover from the coronavirus faster.

At that time, NIAID director Dr. Anthony Fauci said the early results were "a very important proof-of-concept because what it has proven is that a drug can block this virus."

The NIAID trial involved 1,000 patients, showing a 31% faster recovery time, and a slightly lower mortality rate. Remdesivir was originally designed to treat Ebola, but was largely unsuccessful when trialled. A study in 2017 showed it to be effective against human coronaviruses.

Gilead said hospitals with ICUs and hospitals that the federal government decides most need the drug will be prioritized in receiving its limited supply of remdesivir. "Gilead is working with the US government on the logistics of remdesivir distribution and will provide more information when the company begins shipping the drug," the company said Friday.

"We will continue to work with partners across the globe to increase our supply of remdesivir while advancing our ongoing clinical trials to supplement our understanding of the drug's profile," Daniel O'Day, CEO of Gilead Sciences, said in an emailed statement. "We are working to meet the needs of patients, their families and healthcare workers around the world with the greatest sense of urgency and responsibility."

Uplifting scenes of coronavirus solidarity around the world

See all photos
Watch this: Coronavirus drug shows 'clear-cut' evidence of faster recovery, Dr. Fauci says